New Sustained Delivery Method for Lucentis

Genentech, Inc. is testing a less-invasive method of delivery of their anti-VEGF drug Lucentis into the eyes of patients with wet AMD. Currently, anti-VEGF treatments require regular monthly or bi-monthly injections into the back of the eye, which can be taxing on patients’ time and stress level. The new method utilizes a timed release capsule [Read More]

Brain "rewires" itself to enhance other senses in blind people

A common belief that blind people possess unusually heightened non-visual senses now may be more than just a belief. A new study led by Massachusetts Eye and Ear researchers has found that the brains of those who are born blind make new connections in the absence of visual information. This results in heightened senses of hearing, [Read More]

Once-Promising Study of Encapsulated Cell Technology Halted

Researchers have found no significant difference between patients implanted with capsules manufacturing the drug NT-503 and patients receiving anti-VEGF drug injections. As reported on this site in 2015, Neurotech Pharmaceuticals, Inc. announced a Phase 2 clinical study of NT-503 Encapsulated Cell Therapy (ECT) for the treatment of wet age-related macular degeneration (AMD). The study planned [Read More]